Paraproteinemia is the presence of an abnormal protein in the blood, produced when a single clone of immune cells multiplies and churns out identical copies of the same antibody or antibody fragment. These proteins are called monoclonal proteins (or M-proteins), and they show up on routine blood work as an unexpected spike. The condition ranges from completely harmless to a sign of serious blood cancer, depending on the amount of protein and what’s driving the cell growth.
How Monoclonal Proteins Form
Your immune system normally produces a wide variety of antibodies, each made by a different group of plasma cells in your bone marrow. In paraproteinemia, one group of plasma cells begins copying itself excessively, and all the copies produce the exact same antibody molecule. This clonal expansion can be malignant (as in multiple myeloma), premalignant (a precursor state), or entirely benign.
The resulting monoclonal protein can be a complete antibody molecule or just a piece of one. Some clones produce only the lighter portion of the antibody (called a light chain), while others produce the full structure. The type and quantity of protein matter because they determine both the diagnosis and how much damage, if any, the protein causes to organs like the kidneys.
The Most Common Cause: MGUS
The vast majority of people with paraproteinemia have a condition called monoclonal gammopathy of undetermined significance, or MGUS. This is not cancer. It’s defined by three criteria: the M-protein level in the blood is below 3 g/dL, fewer than 10% of bone marrow cells are the abnormal plasma cells, and there’s no organ damage from the protein.
MGUS is surprisingly common, especially with age. Most people who have it will never develop a serious problem from it. However, roughly 1% of people with MGUS progress to multiple myeloma or a related blood cancer each year. That risk is cumulative and lifelong, which is why MGUS requires ongoing monitoring with periodic blood tests rather than treatment.
There are three recognized types of MGUS, each with a slightly different trajectory. The most common type tends to progress toward multiple myeloma. A second type, involving a specific antibody class called IgM, is more likely to progress toward a different blood cancer called Waldenström macroglobulinemia. A third type, light chain MGUS, involves only antibody fragments and can precede a subtype of myeloma that produces only light chains.
When Paraproteinemia Signals Cancer
When the M-protein level climbs to 3 g/dL or higher, or when abnormal plasma cells make up 10% or more of the bone marrow, the condition moves beyond MGUS. If there’s still no organ damage, it’s classified as smoldering multiple myeloma, an intermediate stage that carries a higher risk of progressing to active disease but still doesn’t require immediate treatment.
Active multiple myeloma is diagnosed when the abnormal protein or plasma cells cause specific types of organ damage: weakened bones, anemia, kidney failure, or dangerously high calcium levels. Other malignant conditions associated with paraproteinemia include Waldenström macroglobulinemia and a subset of lymphomas. A small percentage of people monitored for MGUS or smoldering myeloma develop light chain amyloidosis, a condition where misfolded antibody fragments deposit in tissues like the heart, kidneys, and nerves, gradually impairing their function.
How Paraproteinemia Is Detected
The standard screening test is serum protein electrophoresis (SPEP). This separates blood proteins by electrical charge, and a monoclonal protein appears as a sharp, narrow spike in a region where you’d normally see a broad, gentle curve. That spike reflects the flood of identical molecules the abnormal clone is producing.
If a spike is found, a second test called immunofixation electrophoresis confirms the finding and identifies exactly which type of antibody the clone is making. A third test, the serum free light chain assay, measures the smaller antibody fragments circulating in the blood. The normal ratio between the two types of light chains (kappa and lambda) falls between 0.26 and 1.65. A ratio outside that range suggests one clone is overproducing.
These three tests together catch the vast majority of monoclonal proteins, including cases where the clone produces only light chains that wouldn’t show up on a standard electrophoresis screen. Urine testing can also detect light chains that have been filtered through the kidneys.
How Paraproteins Damage the Body
The monoclonal protein itself can cause direct harm, independent of the underlying cancer. Two of the most important complications are kidney damage and hyperviscosity syndrome.
Kidney Damage
Under normal circumstances, light chains are filtered through the kidneys and broken down in the kidney’s tiny tubules. When a clone produces massive quantities of light chains, the tubules become overwhelmed. The excess proteins injure the tubular cells directly and form solid casts that physically block the drainage system of the kidney. This process, called cast nephropathy, is found in 40% to 60% of kidney biopsies from myeloma patients with kidney problems. Normal light chain excretion is under 30 mg per day; in multiple myeloma, it can exceed 20 grams per day.
Hyperviscosity Syndrome
When M-protein levels climb very high, the blood can become too thick to flow normally. The classic signs are nosebleeds and gum bleeding, blurred vision or other visual changes, and neurological symptoms ranging from drowsiness to seizures. The protein level required to trigger this depends on the antibody type. IgM antibodies, which are large molecules, can cause hyperviscosity at lower concentrations (around 5,000 mg/dL), while smaller IgG antibodies typically need to exceed 10,000 mg/dL. It’s rare for hyperviscosity to occur with any monoclonal protein level below 4,000 mg/dL.
Monitoring and What to Expect
If you’ve been told you have paraproteinemia or MGUS, the typical path is regular blood work to track the M-protein level, the free light chain ratio, and basic markers of organ function like kidney values, calcium, and blood counts. The frequency of monitoring depends on your risk level, but many people are checked every 6 to 12 months.
The goal is straightforward: catch any progression early, before significant organ damage occurs. A rising M-protein level, a shifting light chain ratio, or new symptoms like bone pain, unexplained fatigue, or foamy urine can all signal that the condition is advancing. Most people with MGUS live with stable, low-level paraproteinemia for years or decades without ever needing treatment.